• OPEN AN ACCOUNT
Indian Indices
Nifty
25,597.65 -165.70
(-0.64%)
Sensex
83,443.26 -15.89
( -0.02%)
Bank Nifty
57,827.05 -274.40
( -0.47%)
Nifty IT
35,274.55 -378.50
( -1.06%)
Global Indices
Nasdaq
47,337.28 231.03
(0.49%)
Dow Jones
6,818.05 25.50
(0.38%)
Hang Seng
50,848.14 635.87
(1.27%)
Nikkei 225
9,700.69 -0.68
(-0.01%)
Forex
USD-INR
88.68 -0.07
(-0.08%)
EUR-INR
101.96 -0.30
(-0.29%)
GBP-INR
115.92 -0.66
(-0.56%)
JPY-INR
0.58 0.00
(0.22%)

EQUITY - MARKET SCREENER

Addictive Learning Technology Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
92466
INE0RDH01021
48.663002
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LAWSIKHO
23.12
219.55
EPS(TTM)
Face Value()
Div & Yield %
5.97
10
0
 

Lupin reports successful USFDA inspection at New Jersey manufacturing plant
Oct 11,2025

The inspection was conducted over a two-week period, from 29 September to 10 October 2025, and concluded with one observation.

Lupin confirmed that it will address the FDA’s observation promptly and submit a comprehensive response within the stipulated regulatory timeframe.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's consolidated net profit jumped 52.13% to Rs 1,219.03 crore on an 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25.

Shares of Lupin rose 0.11% to end at Rs 1,959.70 on Friday, 10 October 2025.